Global pharma is hitting a major fork in the road, and one way leads to failure. For me, it’s vital that the industry comes together to grasp the once-in-a-generation opportunity that emergent technology is offering.
Founders of early-stage start-ups are passionate, driven and optimistic. So, as they embark on the mission to sell their vision, they should accentuate the positive and keep negative thoughts of risk to the back of their mind, right? Wrong.
AI-based methods are offering superhuman image enhancement. But their medical applications are not without risk – unless, that is, you consider a hybrid approach.
Decarbonising aviation is a herculean task, but the HBx organism holds the potential to radically change both the carbon intensity of transport fuels and the economics of the biofuel industry.
How do we ensure that not only the rich benefit from cell and gene therapy? Rob Collison of Cambridge Consultants says: It’s about more than cutting costs